Literature DB >> 28925583

Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades.

A Nordin1, F Åberg1, E Pukkala2,3, C R Pedersen4, H H Storm5, A Rasmussen4, W Bennet6, M Olausson6, H Wilczek7, B-G Ericzon7, S Tretli8, P-D Line9,10, T H Karlsen9,10,11,12, K M Boberg9,10,11, H Isoniemi1.   

Abstract

Cancer remains one of the most serious long-term complications after liver transplantation (LT). Data for all adult LT patients between 1982 and 2013 were extracted from the Nordic Liver Transplant Registry. Through linkage with respective national cancer-registry data, we calculated standardized incidence ratios (SIRs) based on country, sex, calendar time, and age-specific incidence rates. Altogether 461 cancers were observed in 424 individuals of the 4246 LT patients during a mean 6.6-year follow-up. The overall SIR was 2.22 (95% confidence interval [CI], 2.02-2.43). SIRs were especially increased for colorectal cancer in recipients with primary sclerosing cholangitis (4.04) and for lung cancer in recipients with alcoholic liver disease (4.96). A decrease in the SIR for cancers occurring within 10 years post-LT was observed from the 1980s: 4.53 (95%CI, 2.47-7.60), the 1990s: 3.17 (95%CI, 2.70-3.71), to the 2000s: 1.76 (95%CI, 1.51-2.05). This was observed across age- and indication-groups. The sequential decrease for the SIR of non-Hodgkin lymphoma was 25.0-12.9-7.53, and for nonmelanoma skin cancer 80.0-29.7-10.4. Cancer risk after LT was found to be decreasing over time, especially for those cancers that are strongly associated with immunosuppression. Whether immunosuppression minimization contributed to this decrease merits further study.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  cancer/malignancy/neoplasia: registry/incidence; cancer/malignancy/neoplasia: risk factors; clinical research/practice; liver transplantation/hepatology

Mesh:

Year:  2017        PMID: 28925583     DOI: 10.1111/ajt.14507

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Synovial Cell Sarcoma in an Adolescent Liver Transplant Recipient.

Authors:  Catalina Jaramillo; Ahmed Gilani; Mary Haag; Nathan Donaldson; Cara Mack
Journal:  ACG Case Rep J       Date:  2019-05-16

2.  De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.

Authors:  Tommaso Maria Manzia; Roberta Angelico; Carlo Gazia; Ilaria Lenci; Martina Milana; Oludamilola T Ademoyero; Domiziana Pedini; Luca Toti; Marco Spada; Giuseppe Tisone; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

3.  Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation.

Authors:  Amit Merchea; Faisal Shahjehan; Kristopher P Croome; Jordan J Cochuyt; Zhuo Li; Dorin T Colibaseanu; Pashtoon Murtaza Kasi
Journal:  J Oncol       Date:  2019-02-28       Impact factor: 4.375

4.  Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany.

Authors:  Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

5.  Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.

Authors:  Zhenyu Huo; Caichen Li; Xin Xu; Fan Ge; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Ran Zhong; Bo Cheng; Shan Xiong; Weiyi Lin; Jianxing He; Wenhua Liang
Journal:  Oncoimmunology       Date:  2020-11-29       Impact factor: 8.110

6.  Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland.

Authors:  Terhi Kristiina Friman; Salla Jäämaa-Holmberg; Fredrik Åberg; Ilkka Helanterä; Maija Halme; Markku O Pentikäinen; Arno Nordin; Karl B Lemström; Timo Jahnukainen; Riikka Räty; Birgitta Salmela
Journal:  Int J Cancer       Date:  2022-02-03       Impact factor: 7.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.